REGENXBIO

生物技术研究

Rockville，Maryland 33,760 位关注者

Seeking to improve lives through the curative potential of gene therapy.

查看职位关注

查看全部 362 位员工

关于我们

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.

网站: https://www.regenxbio.com
REGENXBIO的外部链接
所属行业: 生物技术研究
规模: 201-500 人
总部: Rockville，Maryland
类型: 上市公司
创立: 2008
领域: Biotechnology、Biopharmaceuticals和Gene Therapy

地点

主要

9804 Medical Center Dr

US，Maryland，Rockville，20850

获取路线

REGENXBIO员工

查看全部员工

动态

REGENXBIO

33,760 位关注者
14 小时前
举报此动态
Join Jahannaz Dastgir and CureDuchenne on December 3rd at 2:00p.m. EST to hear more about our recent updates from our AFFINITY DUCHENNE trial.
CureDuchenne

5,712 位关注者
1 天前

Please join CureDuchenne and REGENXBIO on Tuesday, December 3rd at 11 AM Pacific | 2 PM Eastern for a community webinar, “RGX-202: AFFINITY DUCHENNE Pivotal Trial and Interim Functional Data.” REGENXBIO will provide an update on its AFFINITY DUCHENNE program of RGX-202, a next-generation micro dystrophin gene therapy. REGENXBIO’s Dr. Naz Dastgir will discuss the company’s pivotal trial plans and share interim clinical data, including the first functional data for RGX-202. Register: https://lnkd.in/gQZAesbz #DMD #duchenne #musculardystrophy #CureDuchenne
赞评论分享
REGENXBIO

33,760 位关注者
19 小时前
举报此动态
Congratulations to Pat Furlong and Parent Project Muscular Dystrophy for 30 years of progress and your immense contributions to the Duchenne community! We are inspired by your dedication and proud to play a role in helping accelerate research leading to potential new therapies for patients living with Duchenne.
1 条评论

赞评论分享
REGENXBIO

33,760 位关注者
1 天前
举报此动态
November is Diabetic Eye Disease Awareness Month. Join us in spreading awareness about the importance of eye health for people living with diabetes. Regular eye exams are vital for early detection of diabetic eye conditions. At REGENXBIO, we believe AAV gene therapy has the potential to transform eye care for people living with diabetic retinopathy. #DiabeticEyeDiseaseAwareness #EyeHealth #GeneTherapy #DiabetesAwareness #DiabeticRetinopathy
赞评论分享
REGENXBIO

33,760 位关注者
5 天前
举报此动态
Join REGENXBIO’s Chief Medical Officer, Steve Pakola, MD, and EVP of Commercial Strategy & Operations, Ram Palanki at #OISXIV as they discuss suprachoroidal drug delivery and innovation in eye care.
Ophthalmology Innovation Source

6,979 位关注者
1 周

?????????? ?????? ?????? ????????! The countdown is on for 2 incredible days of innovation, insights, and networking—kicking off this Friday! We can’t wait to see you there. Let’s make it unforgettable! https://ois.net/ois-xiv/ #OIS #OISXIV #Ophthalmology #Innovation
赞评论分享
REGENXBIO

33,760 位关注者
5 天前
举报此动态
Congratulations, Dr. Muenzer and team, for the grand opening of the UNC Muenzer MPS Research & Treatment Center. We applaud your achievements and your commitment to the MPS community!?

UNC Children's

1,877 位关注者
3 周

Our new UNC Muenzer MPS Research and Treatment Center in Chapel Hill aims to help more children like Cole, who is featured in this video. He has a form of mucopolysaccharidosis (MPS), a rare genetic disorder that can cause physical and neurological symptoms. His mom, Kim Stephens, drove 5.5 hours for treatment from Dr. Joseph Muenzer, MD, PhD, one of the leading MPS experts and the Bryson Distinguished Professor of Pediatrics. Thanks to a $10 million gift from Vaughn and Nancy Bryson, the Muenzer MPS Research and Treatment Center is now open. The center will focus on providing expert care and advancing research to develop new therapies. More info: https://lnkd.in/e7FVPHkd https://lnkd.in/eMSeEMgW

Cole's Story

https://www.youtube.com/

1 条评论

赞评论分享
REGENXBIO

33,760 位关注者
6 天前
举报此动态
Our REGENXBIO Manufacturing Innovation Center was designed to accelerate product development and bring life-changing medicines to patients as quickly as possible. With full, end-to-end capabilities in-house, we’re realizing this vision—reducing supply lead times, and streamlining drug development. A big thank you to the OPTIMA packaging group team for partnering with us to deliver this industry-leading technology for gene therapies!
5 条评论

赞评论分享
REGENXBIO

33,760 位关注者
1 周
举报此动态
At REGENXBIO, we often talk about how “what we do matters” - to patients, to their families, and to their communities. Hear from Marianne Kreiner, Sr. Director, HR Business Partner, as she reflects on what that means, not only for the communities we serve, but also for our people.
1 条评论

赞评论分享
REGENXBIO

33,760 位关注者
1 周
举报此动态
Join Jahannaz Dastgir and Parent Project Muscular Dystrophy to hear more about our recent updates from our AFFINITY DUCHENNE trial.

Parent Project Muscular Dystrophy

3,855 位关注者
1 周

Please join PPMD and REGENXBIO on Wednesday, November 20th at 1 PM ET for a community webinar, “RGX-202: AFFINITY DUCHENNE Pivotal Program and Functional Data.” REGENXBIO will provide an update on its AFFINITY DUCHENNE trial and share interim clinical data for RGX-202, a next-generation microdystrophin gene therapy. PPMD's VP of Clinical Care & Education, Rachel Schrader, MS, APRN, CPNP-PC, and REGENXBIO’s Dr. Naz Dastgir will discuss the company’s pivotal trial plans, explore the first functional data for RGX-202, and offer the Duchenne community an opportunity to ask questions. Register today and submit your questions in advance: https://lnkd.in/effJ_vGH

Webinar: RGX-202 - AFFINITY DUCHENNE Pivotal Program and Functional Data

https://www.parentprojectmd.org

赞评论分享
REGENXBIO

33,760 位关注者
1 周
举报此动态
Today, we announced that AFFINITY DUCHENNE, our potential best-in-class gene therapy for Duchenne, has advanced to pivotal stage and reported positive functional data. Learn more: https://lnkd.in/efSsHHws
4 条评论

赞评论分享
REGENXBIO

33,760 位关注者
1 周
举报此动态
Today, we announced that we will be hosting a webcast to discuss our AFFINITY DUCHENNE pivotal program and new clinical data, including the first functional data from the ongoing Phase I/II study of RGX-202 for the treatment of Duchenne. Learn more: https://lnkd.in/eJNrBekb
1 条评论

赞评论分享

相似主页

查看职位

融资

REGENXBIO 共 10 轮

上一轮

上市后股权 2024年4月6日

US$140,000,000.00

在 Crunchbase 上查看更多信息

登录看看您认识REGENXBIO的哪些人

REGENXBIO

生物技术研究

Rockville，Maryland 33,760 位关注者

Seeking to improve lives through the curative potential of gene therapy.

关于我们

地点

REGENXBIO员工

Ali Zaidi

Win Cheung

Sarah Thomas

Marianne Kreiner

动态

Cole's Story

https://www.youtube.com/

立即加入，查看您错过的职场动态

相似主页

Arcellx

MacroGenics, Inc.

Novavax

Kite Pharma

Sarepta Therapeutics

阿斯利康

Vertex Pharmaceuticals

Regeneron

Emergent BioSolutions

Apogee Therapeutics

查看职位

副董事职位

总监职位

科学家职位

副研究员职位

医学联络员职位

首席科学家职位

毒理学家职位

副总裁职位

工程师职位

工艺流程助理职位

临床专家职位

质量保证经理职位

经理职位

临床操作主任职位

运营总监职位

化学家职位

报销经理职位

行为分析师职位

提案撰稿人职位

临床研究专员职位

融资